文献速递瓣膜病与结构性心脏病

从希波克拉底到生物制剂:心包炎演变史综述

From Hippocrates to Biologics, The Evolving History of Pericarditis: A Review.
PubMed 文献 · Circulation · 2026-09-28

本文综述心包炎从希波克拉底时代的临床观察到现代靶向治疗的历史演变。

要点

  • 秋水仙碱经随机试验确立为急性与复发性心包炎基石治疗。
  • 白细胞介素-1抑制剂用于难治性复发性心包炎。
  • 超声心动图与心脏磁共振实现无创诊断与风险分层。

核心结论

  • 心包炎诊疗已从经验性管理转向基于机制的个体化治疗。
  • 自身炎症机制的识别与白细胞介素-1抑制剂的引入是重要范式转变。

研究设计与样本

  • 本文为叙述性综述,回顾心包炎从希波克拉底时代至生物制剂时代的诊断与治疗演变。

主要发现

  • 19世纪Laennec等工作推动心包炎诊断精确化,后经Spodick与Hatle等 refined。
  • 超声心动图使无创诊断、血流动力学评估与更安全心包穿刺成为可能。
  • 心脏磁共振通过组织特征描述与风险分层进一步推进诊疗。
  • 随机试验确立秋水仙碱为急性和复发性心包炎基石治疗。

关键数值与推荐

  • 秋水仙碱被随机试验确立为急性和复发性心包炎的基石治疗。
  • 白细胞介素-1抑制剂包括阿那白滞素和利洛纳塞普特,尤其用于难治性病例。

临床怎么用

  • 急性与复发性心包炎应将秋水仙碱作为基石治疗。
  • 难治性复发性心包炎可考虑白细胞介素-1抑制剂治疗。
  • 超声心动图与心脏磁共振用于无创诊断、血流动力学评估与风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pericarditis remains a common and clinically relevant cardiovascular condition whose diagnosis and management have evolved substantially over time. Understanding this historical progression provides important context for contemporary practice and emerging therapeutic strategies. Early descriptions, dating back to Hippocrates, framed pericarditis as a clinical observation, with more precise diagnostic characterization emerging in the 19th century through the work of Laennec and later refined by clinicians such as Spodick and Hatle. Initial treatment approaches were largely symptomatic or surgical, including pericardiectomy for advanced constrictive disease. The mid-twentieth century marked a shift toward medical therapy with the introduction of nonsteroidal anti-inflammatory drugs and corticosteroids, which improved symptom control but were limited by high recurrence rates. The advent of echocardiography transformed pericardial disease evaluation by enabling noninvasive diagnosis, hemodynamic assessment, and safer pericardiocentesis. More recently, cardiac magnetic resonance imaging has further advanced care by allowing detailed tissue characterization and improved risk stratification. Randomized trials established colchicine as a cornerstone therapy for both acute and recurrent pericarditis. A major paradigm shift has occurred with the recognition of autoinflammatory mechanisms underlying recurrent disease and the introduction of targeted interleukin-1 inhibition, including anakinra and rilonacept, particularly for refractory cases. Together, these advances reflect a transition from empirical management toward mechanism-based, personalized care. Ongoing progress in imaging, biomarker integration, and targeted immunomodulation is expected to further refine diagnosis, treatment, and long-term outcomes for patients with pericardial disease.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Al-Dalakta A, Tabaja C, Alqahtani M, et al. From Hippocrates to Biologics, The Evolving History of Pericarditis: A Review. Circulation. 2026. PMID: 42804572. doi:10.1161/CIRCULATIONAHA.126.079230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。